Navigation Links
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Date:8/19/2007

Third Phase II Trial Initiated by Myriad For Azixa(TM)

TARRYTOWN, N.Y., Aug. 17 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today reported on new clinical advancements for Azixa(TM)* (MPC-6827), a vascular disrupting agent licensed by the Company to Myriad Genetics, Inc. as part of an exclusive, worldwide development and commercialization agreement.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )

Myriad announced yesterday that it has initiated a third Phase II clinical trial for Azixa in patients with non-small-cell lung cancer that has spread to the brain. The trial is designed to assess Azixa's safety profile and the extent to which it can improve the overall survival of these patients. Two additional Phase II trials for Azixa are underway in primary brain cancer and melanoma that has spread to the brain.

"We are pleased at the clinical advancement Myriad has reported on Azixa, and view it as further evidence of the commercial potential of the compound," stated Jack Talley, President and Chief Executive Officer. "We believe that the study of Azixa in this new indication affords EpiCept with an expanded opportunity to capitalize on the financial benefits associated with our agreement with Myriad, including milestone payments, sublicensing income and potentially future royalties if Azixa continues to progress successfully."

Myriad is responsible for the worldwide development and commercialization of Azixa and any drug candidate that is developed from the series of compounds licensed by EpiCept to Myriad in 2003. The agreement requires that Myriad make future licensing, research and milestone payments to EpiCept, as well as pay a portion of any sublicensing income and pay a royalty on product sales. EpiCept will earn a milestone payment upon the dosing of the first patient in a Phas
'/>"/>

SOURCE EpiCept Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... The prestigious "Discovery or Exploration in History Award" ... Juliana Hillis and Kaylie O’Connell, students at Stoneham High ... Egg, Everything: America’s First IVF Baby". This project was ... History Day program during a week-long final competition judged ... D.C. , The growing popularity of the assisted reproductive ...
(Date:7/28/2014)... developed by researchers at the University of Cambridge, could ... realm of science fiction, such as invisibility cloaks and ... a reality for quite some time, the technique which ... a few billionths of a metre across can be ... them, and works on large chunks all at once. ...
(Date:7/28/2014)... Annapolis Junction, MD (PRWEB) July 28, 2014 ... leader in personalized medicine, will be exhibiting data and ... this year’s International Spine Intervention Society’s (ISIS) ... July 30th-August 3rd, at the Hyatt Regency, in Orlando, ... enhance the knowledge and clinical competence of physicians who ...
(Date:7/28/2014)... Boston, MA (PRWEB) July 28, 2014 ... with two researchers to further develop potential treatments for ... brain tumor, in combination with their patented vaccine platform, ... and Duke University, are based on the work of ... of Neurosurgery at The Preston Robert Tisch Brain Tumor ...
Breaking Biology Technology:In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 3Building 'invisible' materials with light 2Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4
... and minerals. Image courtesy of Brain Twist ... an aid to holding off the cold and flu is ... York-based Brain Twist Inc. is launching Defense Vitamin ... boosting beverage utilizing the FreshCan technology of Degussa FreshTech ...
... Circuit (CAFC) issued a patent-law decision last month that inevitably ... will raise the bar for proving gene and protein related ... fragment sequences were useful. Most notably whether the gene fragments ... patent law. , ,The CAFC ruled against the patent applicants ...
... is bombarded with more than 3,000 advertisements each day. So ... most relevant ones. , ,Marketers used to view advertising ... meant blasting the same ad across mass media as often ... huge audience several times. , ,Jay Townley, president of ...
Cached Biology Technology:Court bars patent protection for certain gene fragments 2Court bars patent protection for certain gene fragments 3Court bars patent protection for certain gene fragments 4Turning ads into sales: Context is king 2Turning ads into sales: Context is king 3Turning ads into sales: Context is king 4
(Date:7/29/2014)... major role in locomotion. Swimming microorganisms, such as bacteria ... compared to the viscous forces exerted by the surrounding ... challenge. Now, scientists have found that the direction of ... that induced by a viscoelastic fluid. These findings have ... Nadal from the Alternative Energies and Atomic Energy Commission ...
(Date:7/29/2014)... But on the remote UK overseas territory of Ascension ... is undergoing something of a renaissance. , Writing in ... the University of Exeter and Ascension Island Government Conservation ... at the remote South Atlantic outpost has increased by ... the 1970s. As many as 24,000 nests are now ...
(Date:7/29/2014)... method to create DNAprotein conjugates. The method can ... , DNA linked to proteins including antibodies ... used in diagnostic techniques, nanotechnology and other disciplines. ... can be used for purposes such as ... The method also provides easier access to handling ...
Breaking Biology News(10 mins):Optimum inertial self-propulsion design for snowman-like nanorobot 2Major turtle nesting beaches protected in 1 of the UK's far flung overseas territories 2New method provides researchers with efficient tool for tagging proteins 2
... at The Wistar Institute announce the release of an ... along a DNA strand that tell a cell,s transcription ... a particular protein. The Mammalian Promoter Database (MPromDb) ... publicly available data on human and mouse genomics. MPromDb ...
... Carnegie Mellon University,s Manojkumar Puthenveedu has discovered the mechanism ... understanding signaling receptor function. Writing in the journal Cell, ... signaling receptor travels back to the cell membrane after ... live on the cell membrane waiting to be matched ...
... Spanish . , The AZTI-Tecnalia technological centre, in ... dairy product companies within the FUTURAL project, has verified that, ... of a number of dairy products, high pressure technology is ... Tecnolat, the results, especially with ready-to-eat fruit products and in ...
Cached Biology News:New annotated database sifts through mountains of sequencing data to find gene promoters 2New annotated database sifts through mountains of sequencing data to find gene promoters 3Carnegie Mellon researchers discover mechanism for signaling receptor recycling 2Carnegie Mellon researchers discover mechanism for signaling receptor recycling 3Research shows positive results with high pressure technology for certain dairy products 2
Bovine Brain Microvascular Endothelial Cells (BBMVEC) (>500,000 cells)...
The improved design and new mechanical solutions of Finnpipette Focus Multichannel Plus improves accuracy and precision.In these low volume multichannel pipettes, the super blow-out function ensures ...
... solution. Cleaves a-(1-3)- and ... and glycoproteins. It is particularly efficient for ... pH must be neutral or above, for ... Unit Definition: One unit will hydrolyze ...
... is specific for human cardiac troponin subunit T, ... signals responsible for contraction of cardiac muscle. It ... in human cells. It also cross-reacts with human ... Antigen: Highly purified human cardiac troponin ...
Biology Products: